Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation

Fig. 3

CXCR7 enhanced immunosuppression of MSCs. a Macrophage apoptosis of LPS-induced THP-1 macrophages (CD11b+ cells) co-cultured with MSCs with or without CXCR7 overexpression for 1 or 3 days. Data are means ± SD (n=9). *P < 0.0001 compared with the vehicle-treated group. # P < 0.001 compared with the groups on day 1. b Differentiation of regulatory T (Treg, FoxP3+ cells)-like cells in Jurkat T cells co-cultured with MSCs with or without CXCR7 overexpression for 1 or 3 days. Data are means ± SD (n=9). *P < 0.001 compared with the vehicle-treated group. # P < 0.001 compared with the groups on day 1. c Macrophage apoptosis of LPS-induced THP-1 macrophages co-cultured with MSCs with or without the CXCR7 antagonist, CCX771, or agonist, TC14012, treatment for 3 days. Data are means ± SD (n=9). *P < 0.001 compared with the untreated group (WT). d Differentiation of regulatory T-like cells in Jurkat T cells co-cultured with MSCs with or without CCX771 or TC14012 treatment for 3 days. Data are means ± SD (n=9). *P < 0.001 compared the untreated group (WT). e Changes in the expression of genes associated with soluble factors secreted by MSCs with or without CXCR7 overexpression during immunomodulation. Data are means ± SD (n=6). *P < 0.001 compared the control MSCs without lentiviral transduction (WT). f The protein levels of IL-10, LIF, PGE2, and NO in the condition medium of MSCs with or without CXCR7 overexpression. Data are means ± SD (n=6). *P < 0.0001 compared with the control MSCs without lentiviral transduction (WT). g Protein levels of IL-10, LIF, PGE2, and NO in the condition medium of MSCs with or without CCX771 or TC14012 treatment for 3 days. Data are means ± SD (n=6). *P < 0.001 compared with the untreated group (WT)

Back to article page